MGAT5 and breast carcinoma: Overexpression of Mgat5 has been linked to tumor aggressiveness and poor prognosis in multiple cancer types, including colorectal, endometrial, hepatocellular, and gastric cancers (13–16), whereas loss of Mgat5 has been associated with decreased tumor growth in multiple cancers both in vitro and in vivo, including colorectal cancer (13, 17), breast cancer (18, 19), nasopharyngeal carcinoma (20), lung adenocarcinoma (21), hepatocellular carcinoma (HCC) (22–24), and gastric cancer (25).